Evidence map›Paper›PMID 22076155›Full record

ArticlePloS one2011

LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer.

Linda M Liao, Paul Brennan, Dana M van Bemmel, David Zaridze, Vsevolod Matveev, Vladimir Janout, Hellena Kollarova, Vladimir Bencko, Marie Navratilova, Neonila Szeszenia-Dabrowska and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Advanced biomedical research · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. The epigenetic landscape of renal cancer.Nature reviews. Nephrology · 2017
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Linda M LiaoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America. liaolm@mail.nih.gov
Paul Brennan
Dana M van Bemmel
David Zaridze
Vsevolod Matveev
Vladimir Janout
Hellena Kollarova
Vladimir Bencko
Marie Navratilova
Neonila Szeszenia-Dabrowska
Dana Mates
Nathaniel Rothman
Paolo Boffetta
Wong-Ho Chow
Lee E Moore
National Cancer Institute · USDivision of Cancer Epidemiology and GeneticsPalacký University Olomouc · CZCentre International de Recherche sur le Cancer · FRCharles University · CZInternational Prevention Research Institute · FRMasaryk Memorial Cancer Institute · CZNofer Institute of Occupational Medicine · PL

Funding

Studies of Occupational CancerZIACP010120 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI LAN, QING · 2009 to 2025
$34.4M
Intramural NIH HHS
6 · The paper itself

Abstract

purposeLeukocyte global DNA methylation levels are currently being considered as biomarkers of cancer susceptibility and have been associated with risk of several cancers. In this study, we aimed to examine the association between long interspersed nuclear elements (LINE-1) methylation levels, as a biomarker of global DNA methylation in blood cell DNA, and renal cell cancer risk. EXPERIMENTAL

designLINE-1 methylation of bisulfite-converted genomic DNA isolated from leukocytes was quantified by pyrosequencing measured in triplicate, and averaged across 4 CpG sites. A total of 328 RCC cases and 654 controls frequency-matched(2∶1) on age(±5years), sex and study center, from a large case-control study conducted in Central and Eastern Europe were evaluated.

resultsLINE-1 methylation levels were significantly higher in RCC cases with a median of 81.97% (interquartile range[IQR]: 80.84-83.47) compared to 81.67% (IQR: 80.35-83.03) among controls (p = 0.003, Wilcoxon). Compared to the lowest LINE-1 methylation quartile(Q1), the adjusted ORs for increasing methylation quartiles were as follows: OR(Q2) = 1.84(1.20-2.81), OR(Q3) = 1.72(1.11-2.65) and OR(Q4) = 2.06(1.34-3.17), with a p-trend = 0.004. The association was stronger among current smokers (p-trend<0.001) than former or never smokers (p-interaction = 0.03). To eliminate the possibility of selection bias among controls, the relationship between LINE-1 methylation and smoking was evaluated and confirmed in a case-only analysis, as well.

conclusionsHigher levels of LINE-1 methylation appear to be positively associated with RCC risk, particularly among current smokers. Further investigations using both post- and pre-diagnostic genomic DNA is warranted to confirm findings and will be necessary to determine whether the observed differences occur prior to, or as a result of carcinogenesis.

Indexed as

DNA MethylationAdultAgedBiomarkers, TumorCarcinoma, Renal CellCase-Control StudiesDNAEurope, EasternFemaleHumansKidney NeoplasmsLeukocytesLong Interspersed Nucleotide ElementsMaleMiddle AgedRisk FactorsBiomarkers, TumorDNA

Identifiers

PMID22076155
PMCPMC3208631
OpenAlexW1994237694

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.